Simultaneous hyperthermia-chemotherapy effect by arterial injection of Fe(Salen) for femur tumor.
Animals
Carcinoma, Squamous Cell
/ therapy
Cell Line, Tumor
Cell Survival
/ drug effects
Drug Delivery Systems
/ methods
Femoral Neoplasms
/ therapy
Humans
Hyperthermia, Induced
/ methods
Injections, Intra-Arterial
Injections, Intravenous
Iron Compounds
/ administration & dosage
Magnetic Fields
Male
Methotrexate
/ administration & dosage
Nanoparticles
/ administration & dosage
Rabbits
Rats, Sprague-Dawley
Xenograft Model Antitumor Assays
Fe(Salen)
alternating current magnetic field
arterial injection
femur tumor
hyperthermia
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
20
09
2018
revised:
12
10
2018
accepted:
23
10
2018
pubmed:
31
10
2018
medline:
15
1
2019
entrez:
31
10
2018
Statut:
ppublish
Résumé
We previously identified a novel nanomagnetic particle, N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)]. Fe(Salen) not only shows antitumor effects but also magnetic properties. We found that Fe(Salen) can be used for magnet-guided drug delivery and visualization of accumulated drug by magnetic resonance imaging (MRI) because of its magnetism. In addition, Fe(Salen) can generate heat by itself when exposed to an alternating current magnetic field (AMF), resulting in a hyperthermia effect. Herein, we partly elucidated the antitumor mechanism of Fe(Salen) and carried out an i.v. repeated dose toxicity study to decide the therapeutic amount. Furthermore, we evaluated the antitumor effect of selective intra-arterial injection or i.v. injection of Fe(Salen) by catheter and the hyperthermia effect of Fe(Salen) when exposed to AMF in vivo. We used a rabbit model grafted with VX2 cells (rabbit squamous cell carcinoma) on the right leg. Intra-arterial injection of Fe(Salen) showed a greater antitumor effect than did i.v. injection. The combination of Fe(Salen) intra-arterial injection and AMF exposure showed a greater antitumor effect than did either Fe(Salen) or methotrexate (MTX) without AMF exposure, suggesting that AMF exposure greatly enhanced the antitumor effect of Fe(Salen) by arterial injection by catheter. This is the first report that the effectiveness of Fe(Salen) was evaluated in the point of administration route; that is, selective intra-arterial injection by catheter. Taken together, these results indicate a new administration route; that is, selective arterial injection of Fe(Salen) by catheter, and the development of a new strategy of simultaneous hyperthermia-chemotherapy in the future.
Identifiants
pubmed: 30375142
doi: 10.1111/cas.13851
pmc: PMC6317948
doi:
Substances chimiques
Iron Compounds
0
mu-oxo N,N'- bis(salicylidene)ethylenediamine iron
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-365Subventions
Organisme : Japan Society for the Promotion of Science (JSPS) AKENHI Grant
ID : 24390200
Organisme : Japan Society for the Promotion of Science (JSPS) AKENHI Grant
ID : 25670131
Organisme : Japan Society for the Promotion of Science (JSPS) AKENHI Grant
ID : 26870481
Organisme : the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grant
ID : 22136009
Organisme : the Japan Agency for Medical Research and Development (AMED)
ID : 66890005
Organisme : the Japan Agency for Medical Research and Development (AMED)
ID : 66890011
Organisme : the Japan Agency for Medical Research and Development (AMED)
ID : 66890001
Organisme : the Japan Agency for Medical Research and Development (AMED)
ID : 66890023
Organisme : Takeda Science Foundation
Organisme : SGH Foundation
Organisme : Japan Research Foundation for Clinical Pharmacology
Informations de copyright
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Pharm Res. 1998 Jan;15(1):133-8
pubmed: 9487560
Apoptosis. 1997;2(6):510-7
pubmed: 14646522
Cold Spring Harb Protoc. 2011 Aug 01;2011(8):990-2
pubmed: 21807856
J Physiol Sci. 2017 Jul;67(4):497-505
pubmed: 27613608
J Pharmacol Sci. 2017 Aug;134(4):203-210
pubmed: 28779994
Sci Rep. 2016 Apr 22;6:24629
pubmed: 27103308
J Physiol Sci. 2014 May;64(3):177-83
pubmed: 24619404
Biomaterials. 2011 Mar;32(7):1890-905
pubmed: 21167595
Cell Res. 2008 Feb;18(2):254-67
pubmed: 18227858
Oncology. 2018;94(6):354-362
pubmed: 29656296
Cell Res. 2002 Mar;12(1):9-18
pubmed: 11942415
Sci Rep. 2017 Feb 20;7:42783
pubmed: 28218292
Cancer Res. 2005 Apr 1;65(7):2861-71
pubmed: 15805288
J Recept Signal Transduct Res. 2015;35(6):600-4
pubmed: 26096166
Oral Oncol. 1998 Sep;34(5):387-90
pubmed: 9861346
Front Pharmacol. 2016 Mar 29;7:77
pubmed: 27064563
Cancer Sci. 2019 Jan;110(1):356-365
pubmed: 30375142
Cancer Res. 1985 Jan;45(1):398-405
pubmed: 3917374
PLoS One. 2014 Feb 21;9(2):e89292
pubmed: 24586666
J Bone Joint Surg Am. 2004 Aug;86(8):1684-9
pubmed: 15292415
Cancer Sci. 2018 Nov;109(11):3483-3493
pubmed: 30155931
Mol Pharmacol. 2004 Jun;65(6):1427-39
pubmed: 15155836
Sci Rep. 2015 Mar 17;5:9194
pubmed: 25779357